Effects of simvastatin on cell proliferation and immune escape of non-small cell lung cancer
LIU Bing
YANG Jie
Abstract： Objective To evaluate the effects of simvastatin on cell proliferation and immune escape of hu -man non-small cell lung cancer ( NSCLC) as well as the underlying mechanisms .Methods Cell proliferation was de-termined using a modified MTT assay after the treatment with different concentrations of simvastatin , or RhoA siRNA in A549 cells.The gene expression of anti-immune escape factor , major histocompatibility complex class Ⅰ( MHCⅠ, also known as HLA-A) and peptide transporter protein ( TAP1) were detected by real-time RT-PCR.The change of RhoA activity was measured by a microplate reader in A 549 cells treated with simvastatin , or RhoA siRNA.SiRNA transfection was done using lipofectamine 2000 .Results Simvastatin ( 10 ~30 μmol/L ) significantly reduced the proliferation, enhanced gene expression of HLA-A and TAP1 and inhibited RhoA activity of A549 cells in concentra-tion-dependent manner (P<0.05 or P<0.01).Moreover, inhibition of RhoA activity with 0.1 μmol/L RhoA siR-NA also resulted in a substantial inhibition of proliferation and increased gene expression of HLA-A and TAP1 of 549 cells(P<0.01).However, combination treatment of RhoA siRNA and simvastatin exerted no synergistic effects in 549 cells compared with the specific siRNA treatment alone (P>0.05).Conclusion Simvastatin can suppress A549 cells proliferation and immune escape primarily through inhibition of RhoA activity and thereby increasing the gene expression of HLA-A and TAP1.
Keywords：SimvastatinNon-small cell lung cancer ( NSCLC)Cell proliferationImmune escapeRhoA
Publication Date：2013-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 729-732 )